

Clinical Trial Protocol

Iranian Registry of Clinical Trials

23 Jun 2026

Assessing the effect of zinc supplementation on lipid profile, hs-CRP, the frequency of migraine attacks and its duration and severity in adult women

Protocol summary

Study aim

Effect of zinc gluconate supplementation on serum hs-CRP, lipid profile, frequency of migraine attacks and its severity and duration in adult women

Design

A parallel double-blind randomized clinical trial (both patients and researchers). Randomization was performed using computer-generated random numbers.

Settings and conduct

Sample size and population: 60 women with migraine headache were selected and referred to the neurology clinic of Imam Khomeini Medical Center affiliated to Urmia University of Medical Sciences, Urmia, Iran.

Participants/Inclusion and exclusion criteria

Inclusion criteria: 18-55 years old, female, resident of Urmia, having episodic or chronic migraines, interested in participating in the exclusion criteria: using any supplement in the last 3 months, pregnancy, lactation, smoking 2 years history of head and neck surgery, history of vasculitis, malignancies, AIDS, history of diabetes and stroke, cardiovascular disease, asthma, rheumatoid arthritis, liver and kidney failure, kidney stones, lipid profile lowering drugs, medication use Nonsteroidal anti-inflammatory, history of mental disorders, hypertension, gastrointestinal diseases, lupus

Intervention groups

Patients were divided into two groups to receive 15 mg zinc gluconate (intervention group: n = 30) and placebo (control group: n = 30). Fasting blood samples were taken at baseline and 12 weeks after the intervention to determine serum zinc, lipid profile and hs-CRP.

Intervention time: 12 weeks

Main outcome variables

Frequency, severity and duration of migraine attacks (primary outcome) Serum levels of zinc, cholesterol, triglycerides, LDL, HDL and hs-CRP (secondary outcome)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191014045100N1**

Registration date: **2020-02-18, 1398/11/29**

Registration timing: **retrospective**

Last update: **2020-02-18, 1398/11/29**

Update count: **0**

Registration date

2020-02-18, 1398/11/29

Registrant information

Name

monireh mazaheri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 4222 2893

Email address

mazaheri.m@umsu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-03-21, 1398/01/01

Expected recruitment end date

2019-06-20, 1398/03/30

Actual recruitment start date

2019-03-21, 1398/01/01

Actual recruitment end date

2019-08-16, 1398/05/25

Trial completion date

2019-11-21, 1398/08/30

Scientific title

Assessing the effect of zinc supplementation on lipid profile, hs-CRP, the frequency of migraine attacks and its duration and severity in adult women

Public title

Effect of supplementation on the treatment of migraine headaches

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Age range 18-55 years female Resident of Urmia Having episodic or chronic migraines Interested in collaborating in the study with a 3-month intervention

Exclusion criteria:

Use of any supplement or multivitamin - mineral in the last 3 months Pregnancy Breastfeeding smoking History of serious head trauma or head and neck surgery in the past 2 years A history of vasculitis Malignancies AIDS History of diabetes History of stroke and coronary artery disease Cardiovascular disease Asthma Rheumatoid Arthritis Kidney or liver failure kidney stone Use of drugs that decrease lipid profile (total cholesterol, TG, LDL-C) Taking non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen (for more than 15 days per month in the last 3 months) History of mental disorders such as depression blood pressure Digestive diseases 21. Lupus

Age

From **18 years** old to **55 years** old

Gender

Female

Phase

3

Groups that have been masked

- Participant
- Investigator
- Outcome assessor

Sample size

Target sample size: **60**

Actual sample size reached: **61**

Randomization (investigator's opinion)

Randomized

Randomization description

At the beginning of the study, participants were randomly divided into two groups of 30 intervention and placebo with 1: 1 allocation ratio. Random block method was used for this purpose and the random numbers required for this method were generated using RAS software. Random-sized blocks of 4 and 6 were used to keep the study blind. Random numbers were generated by the project statistical consultant.

Blinding (investigator's opinion)

Double blinded

Blinding description

Participants and either the researchers or the evaluators of the outcome were unaware of the allocation of study groups.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Urmia University of Medical Sciences

Street address

Urmia, Apadana intersection, Zaker street, Bostan dormitory

City

urmia

Province

West Azarbaijan

Postal code

6257757168

Approval date

2019-04-28, 1398/02/08

Ethics committee reference number

IR.UMSU.REC.1398.045

Health conditions studied**1****Description of health condition studied**

Migraine

ICD-10 code

G43

ICD-10 code description

Migraine

Primary outcomes**1****Description**

Frequency of migraine attacks

Timepoint

At baseline (before intervention) and 30, 60, and 90 days after starting zinc gluconate supplementation

Method of measurement

Monthly Notepad

2**Description**

The severity of migraine attacks

Timepoint

At baseline (before intervention) and 30, 60 and 90 days after zinc gluconate supplementation

Method of measurement

Pain severity questionnaire NRS (Numeric Rating Scale)

3

Description

The period of migraine attacks

Timepoint

At baseline (before intervention) and 30, 60 and 90 days after zinc gluconate supplementation

Method of measurement

Monthly Notepad

Secondary outcomes

1

Description

serum level of zinc

Timepoint

At baseline (before intervention) and 90 days after zinc gluconate supplementation

Method of measurement

dialab kit of zinc

2

Description

Serum cholesterol level

Timepoint

At baseline (before intervention) and 90 days after zinc gluconate supplementation

Method of measurement

pars azmun kit

3

Description

Serum triglyceride levels

Timepoint

At baseline (before intervention) and 90 days after zinc gluconate supplementation

Method of measurement

pars azmun kit

4

Description

serum level of Low Density Lipoprotein (LDL)

Timepoint

At baseline (before intervention) and 90 days after zinc gluconate supplementation

Method of measurement

pars azmun kit

5

Description

serum level of High Density Lipoprotein (HDL)

Timepoint

At baseline (before intervention) and 90 days after zinc gluconate supplementation

Method of measurement

pars azmun kit

6

Description

serum level of high sensitivity C-Reactive Protein (hs-CRP)

Timepoint

At baseline (before intervention) and 90 days after zinc gluconate supplementation

Method of measurement

pars azmun kit

Intervention groups

1

Description

Intervention group: Zinc Gluconate tablets, 15 mg, daily, orally for 12 weeks

Category

Treatment - Drugs

2

Description

Intervention group: Placebo tablets, 15 mg, daily, orally for 12 weeks

Category

Placebo

Recruitment centers

1

Recruitment center**Name of recruitment center**

Imam Khomeini Hospital

Full name of responsible person

Monireh Mazaheri

Street address

Urmia, Apadana intersection, Zaker street, Bostan dormitory

City

Urmia

Province

West Azarbaijan

Postal code

6257757168

Phone

+98 44 3346 9935

Email

mazaheri.m@umsu.ac.ir

Sponsors / Funding sources

1

Sponsor**Name of organization / entity**

Oroumia University of Medical Sciences

Full name of responsible person

Rasoul Zarrin

Street address

Urmia, Imam Reza Street, 12 meters, No. 56

City

Urmia

Province

West Azarbaijan

Postal code

6257757168

Phone

+98 44 3346 9935

Email

rasoul.zarrin@uqconnect.edu.au

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Oroumia University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Oroumia University of Medical Sciences

Full name of responsible person

Rasoul Zarrin

Position

Faculty member

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Urmia St., Imam Reza Street, 12 meters south of No. 56

City

Urmia

Province

West Azarbaijan

Postal code

6257757168

Phone

+98 44 3346 9935

Email

rasoul.zarrin@uqconnect.edu.au

Person responsible for scientific inquiries

Contact

Name of organization / entity

Oroumia University of Medical Sciences

Full name of responsible person

Rasoul Zarrin

Position

Faculty member

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Urmia St., Imam Reza Street, 12 meters south of No. 56

City

Urmia

Province

West Azarbaijan

Postal code

6257757168

Phone

+98 44 3346 9935

Email

rasoul.zarrin@uqconnect.edu.au

Person responsible for updating data

Contact

Name of organization / entity

Oroumia University of Medical Sciences

Full name of responsible person

Monireh Mazaheri

Position

Student

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

Bostan dormitory, urmia

City

Urmia

Province

West Azarbaijan

Postal code

6257757168

Phone

+98 31 4222 2893

Fax

Email

mazaheri.m@umsu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available